We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

213 hedge funds and large institutions have $611M invested in Vir Biotechnology in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 81 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more call options, than puts

Call options by funds: $1.44M | Put options by funds: $742K

9% more capital invested

Capital invested by funds: $558M → $611M (+$52.6M)

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

0% more funds holding

Funds holding: 213 → 213 (0)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3.1% less ownership

Funds ownership: 80.13% → 77.03% (-3.1%)

25% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 81

Holders
213
Holders Change
–
Holders Change %
0%
% of All Funds
2.8%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
28
Increased
61
Reduced
81
Closed
26
Calls
$1.44M
Puts
$742K
Net Calls
+$702K
Net Calls Change
-$234K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$5.4M
2
Millennium Management
Millennium Management
New York
+$4.03M
3
Aberdeen Group
Aberdeen Group
United Kingdom
+$2.66M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.43M
5
PAM
Panagora Asset Management
Massachusetts
+$1.35M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$13.6M
2
Artisan Partners
Artisan Partners
Wisconsin
-$3.99M
3
IC
Ikarian Capital
Texas
-$2.43M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$2.19M
5
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$1.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
51
RhumbLine Advisers
Massachusetts
$1.3M -$11K -2,150 -0.9%
UBS Group
52
UBS Group
Switzerland
$1.23M -$513K -100,405 -32%
Franklin Resources
53
Franklin Resources
California
$1.18M -$239K -46,720 -18%
N
54
Nuveen
North Carolina
$1.17M – – –
Deutsche Bank
55
Deutsche Bank
Germany
$1.16M +$38.9K +7,609 +4%
Ameriprise
56
Ameriprise
Minnesota
$1.11M -$87.5K -17,119 -8%
HF
57
HRT Financial
New York
$1.01M -$29.4K -5,745 -3%
Swiss National Bank
58
Swiss National Bank
Switzerland
$972K – – –
LP
59
LMR Partners
United Kingdom
$958K – – –
SCM
60
Stonepine Capital Management
Oregon
$914K +$153K +30,000 +23%
ECM
61
ExodusPoint Capital Management
New York
$913K +$546K +106,874 +202%
BFM
62
Boothbay Fund Management
New York
$903K -$759K -148,422 -48%
AQR Capital Management
63
AQR Capital Management
Connecticut
$869K -$1.52M -296,667 -66%
SCM
64
Superstring Capital Management
New York
$858K +$769K +150,312 New
UBS AM
65
UBS AM
Illinois
$822K -$769K -150,445 -51%
DFCM
66
Dark Forest Capital Management
Puerto Rico
$817K +$732K +143,068 New
XT
67
XTX Topco
Cayman Islands
$799K +$715K +139,896 New
Walleye Capital
68
Walleye Capital
New York
$793K -$231K -45,100 -25%
Rafferty Asset Management
69
Rafferty Asset Management
New York
$655K -$88.1K -17,236 -13%
AllianceBernstein
70
AllianceBernstein
Tennessee
$626K – – –
California State Teachers Retirement System (CalSTRS)
71
California State Teachers Retirement System (CalSTRS)
California
$618K +$128K +25,118 +30%
Mirae Asset Global ETFs Holdings
72
Mirae Asset Global ETFs Holdings
Hong Kong
$605K +$542K +105,965 New
Jacobs Levy Equity Management
73
Jacobs Levy Equity Management
New Jersey
$552K -$248K -48,581 -33%
Acadian Asset Management
74
Acadian Asset Management
Massachusetts
$539K +$485K +94,801 New
New York State Teachers Retirement System (NYSTRS)
75
New York State Teachers Retirement System (NYSTRS)
New York
$473K +$2.56K +500 +0.6%
1 2
3
4 5

VIR Hedge Fund Activity: Q3 2025 in Review

213 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q3 2025, worth a combined $611M — up 9.4% from $558M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VIR positions and 26 closed out — a net gain of 2 holders — while 61 added to existing stakes and 81 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $5.4M. The largest seller was Citadel Advisors, cutting an estimated $13.6M.

  • 213 institutional investors held Vir Biotechnology (VIR) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $611M of Vir Biotechnology stock for Q3 2025, up 9.4% quarter-over-quarter.
  • 28 funds opened new Vir Biotechnology positions in Q3 2025 and 26 closed out, a net change of +2 holders.
  • The largest Vir Biotechnology buyer in Q3 2025 was Morgan Stanley, an estimated $5.4M added.
  • The largest Vir Biotechnology seller in Q3 2025 was Citadel Advisors, an estimated $13.6M sold.

Based on aggregated 13F filings for Q3 2025.